Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-08-02

AUTHORS

Neil A. Accortt, Jennifer Schenfeld, Eunice Chang, Elya Papoyan, Michael S. Broder

ABSTRACT

IntroductionEffective treatment for rheumatoid arthritis (RA) may lead to lower overall and RA-related healthcare utilization. We evaluated healthcare utilization before and after initiation of the tumor necrosis factor inhibitor etanercept in patients with moderate to severe RA.MethodsThis retrospective cohort study used data from the MarketScan® claims database. Data from adult patients with RA newly exposed to etanercept between January 1, 2010 and December 31, 2013 were analyzed. Patients had at least one inpatient or outpatient claim for RA and at least one claim for etanercept (first claim was index date). Etanercept compliance was determined on the basis of proportion of days covered (PDC). Primary outcome was change in overall and RA-related healthcare utilization in the year before and year after etanercept initiation. McNemar’s test and paired t test, respectively, were used to determine statistical significance for dichotomous and continuous variables.ResultsData from 6737 patients were analyzed; mean age was 49.8 years and 77.3% were female. Overall outpatient services, office visits, outpatient hospital services, laboratory visits, and emergency department visits were significantly lower in the post-index period compared to pre-index. RA-related pharmacotherapy use (oral corticosteroids, opioid analgesics, nonsteroidal anti-inflammatory drugs, and nonbiologic disease-modifying antirheumatic drugs) was significantly lower in the post-index period compared to pre-index. Rates of RA-related total joint arthroplasty, joint reconstructions, and soft tissue procedures were similar in pre-index and post-index periods. High etanercept compliance (PDC ≥80%) was associated with significantly lower rates of RA-related outpatient services, office visits, diagnostic imaging studies, and joint reconstructions compared with noncompliance.ConclusionOverall healthcare utilization decreased after etanercept initiation. Patients who were most compliant with etanercept had significantly lower utilization than less compliant patients.FundingAmgen, Inc More... »

PAGES

2093-2103

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-017-0596-6

DOI

http://dx.doi.org/10.1007/s12325-017-0596-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090949218

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28770517


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents, Non-Steroidal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delivery of Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etanercept", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insurance Claim Review", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Accortt", 
        "givenName": "Neil A.", 
        "id": "sg:person.0725420006.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725420006.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "DOCS Global, Inc., Pennbrook Pkwy, North Wales, PA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "DOCS Global, Inc., Pennbrook Pkwy, North Wales, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schenfeld", 
        "givenName": "Jennifer", 
        "id": "sg:person.0621653226.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621653226.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Partnership for Health Analytic Research, Beverly Hills, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.430055.7", 
          "name": [
            "Partnership for Health Analytic Research, Beverly Hills, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chang", 
        "givenName": "Eunice", 
        "id": "sg:person.013221263257.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013221263257.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Partnership for Health Analytic Research, Beverly Hills, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.430055.7", 
          "name": [
            "Partnership for Health Analytic Research, Beverly Hills, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papoyan", 
        "givenName": "Elya", 
        "id": "sg:person.012257341513.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012257341513.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Partnership for Health Analytic Research, Beverly Hills, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.430055.7", 
          "name": [
            "Partnership for Health Analytic Research, Beverly Hills, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Broder", 
        "givenName": "Michael S.", 
        "id": "sg:person.01174636717.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174636717.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-016-3277-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036632859", 
          "https://doi.org/10.1007/s10067-016-3277-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-08-02", 
    "datePublishedReg": "2017-08-02", 
    "description": "IntroductionEffective treatment for rheumatoid arthritis (RA) may lead to lower overall and RA-related healthcare utilization. We evaluated healthcare utilization before and after initiation of the tumor necrosis factor inhibitor etanercept in patients with moderate to severe RA.MethodsThis retrospective cohort study used data from the MarketScan\u00ae claims database. Data from adult patients with RA newly exposed to etanercept between January 1, 2010 and December 31, 2013 were analyzed. Patients had at least one inpatient or outpatient claim for RA and at least one claim for etanercept (first claim was index date). Etanercept compliance was determined on the basis of proportion of days covered (PDC). Primary outcome was change in overall and RA-related healthcare utilization in the year before and year after etanercept initiation. McNemar\u2019s test and paired t test, respectively, were used to determine statistical significance for dichotomous and continuous variables.ResultsData from 6737 patients were analyzed; mean age was 49.8\u00a0years and 77.3% were female. Overall outpatient services, office visits, outpatient hospital services, laboratory visits, and emergency department visits were significantly lower in the post-index period compared to pre-index. RA-related pharmacotherapy use (oral corticosteroids, opioid analgesics, nonsteroidal anti-inflammatory drugs, and nonbiologic disease-modifying antirheumatic drugs) was significantly lower in the post-index period compared to pre-index. Rates of RA-related total joint arthroplasty, joint reconstructions, and soft tissue procedures were similar in pre-index and post-index periods. High etanercept compliance (PDC \u226580%) was associated with significantly lower rates of RA-related outpatient services, office visits, diagnostic imaging studies, and joint reconstructions compared with noncompliance.ConclusionOverall healthcare utilization decreased after etanercept initiation. Patients who were most compliant with etanercept had significantly lower utilization than less compliant patients.FundingAmgen, Inc", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-017-0596-6", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "post-index period", 
      "rheumatoid arthritis", 
      "healthcare utilization", 
      "etanercept initiation", 
      "office visits", 
      "outpatient services", 
      "tumor necrosis factor inhibitor etanercept", 
      "MethodsThis retrospective cohort study", 
      "rate of RA", 
      "retrospective cohort study", 
      "severe rheumatoid arthritis", 
      "emergency department visits", 
      "retrospective claims analysis", 
      "total joint arthroplasty", 
      "soft tissue procedures", 
      "diagnostic imaging studies", 
      "joint reconstruction", 
      "outpatient hospital services", 
      "pharmacotherapy use", 
      "cohort study", 
      "adult patients", 
      "compliant patients", 
      "primary outcome", 
      "department visits", 
      "outpatient claims", 
      "mean age", 
      "joint arthroplasty", 
      "tissue procedures", 
      "patients", 
      "imaging studies", 
      "etanercept", 
      "hospital services", 
      "McNemar test", 
      "visits", 
      "statistical significance", 
      "laboratory visits", 
      "arthritis", 
      "t-test", 
      "continuous variables", 
      "lower rates", 
      "claims analysis", 
      "basis of proportion", 
      "initiation", 
      "years", 
      "low utilization", 
      "MarketScan", 
      "inpatients", 
      "ResultsData", 
      "arthroplasty", 
      "compliance", 
      "period", 
      "outcomes", 
      "age", 
      "treatment", 
      "noncompliance", 
      "test", 
      "study", 
      "days", 
      "rate", 
      "changes", 
      "proportion", 
      "utilization", 
      "reconstruction", 
      "services", 
      "data", 
      "database", 
      "significance", 
      "procedure", 
      "use", 
      "variables", 
      "analysis", 
      "basis", 
      "claims"
    ], 
    "name": "Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis", 
    "pagination": "2093-2103", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090949218"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-017-0596-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28770517"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-017-0596-6", 
      "https://app.dimensions.ai/details/publication/pub.1090949218"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_733.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-017-0596-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0596-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0596-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0596-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0596-6'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      113 URIs      104 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-017-0596-6 schema:about N2226f3d439534a38b3475553fec34c4d
2 N26ac8bc150484144b8f78e0bb4f044ef
3 N33d5478613764c2386534d5ecae4d91a
4 N4f957c48cd4243b099c876cd7e5bd0af
5 N56dafb4c91b74c89bea8d36c3f73feba
6 N64df56efa3ed4caeab6fb95e4bee4bcd
7 N6ee9700255e046a18719b6d978875ed9
8 N738233abf1764224a5efd5a97a6e3bd6
9 N7a30c135e0db45f7b873bf8c05c6593a
10 N7a944a74d1dc4000a67759766ffed146
11 Nb8c9b68026364895a03b24f0cb61a9b4
12 Nea70ee3331c446c3baa1e8b308de72f0
13 Nf0707316c19c4e339a2dbbc020bb0c4c
14 Nfafdf169a2624e4a9b68158dbe64543d
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N364890dd9e334962b641758cdc926b18
18 schema:citation sg:pub.10.1007/s10067-016-3277-y
19 schema:datePublished 2017-08-02
20 schema:datePublishedReg 2017-08-02
21 schema:description IntroductionEffective treatment for rheumatoid arthritis (RA) may lead to lower overall and RA-related healthcare utilization. We evaluated healthcare utilization before and after initiation of the tumor necrosis factor inhibitor etanercept in patients with moderate to severe RA.MethodsThis retrospective cohort study used data from the MarketScan® claims database. Data from adult patients with RA newly exposed to etanercept between January 1, 2010 and December 31, 2013 were analyzed. Patients had at least one inpatient or outpatient claim for RA and at least one claim for etanercept (first claim was index date). Etanercept compliance was determined on the basis of proportion of days covered (PDC). Primary outcome was change in overall and RA-related healthcare utilization in the year before and year after etanercept initiation. McNemar’s test and paired t test, respectively, were used to determine statistical significance for dichotomous and continuous variables.ResultsData from 6737 patients were analyzed; mean age was 49.8 years and 77.3% were female. Overall outpatient services, office visits, outpatient hospital services, laboratory visits, and emergency department visits were significantly lower in the post-index period compared to pre-index. RA-related pharmacotherapy use (oral corticosteroids, opioid analgesics, nonsteroidal anti-inflammatory drugs, and nonbiologic disease-modifying antirheumatic drugs) was significantly lower in the post-index period compared to pre-index. Rates of RA-related total joint arthroplasty, joint reconstructions, and soft tissue procedures were similar in pre-index and post-index periods. High etanercept compliance (PDC ≥80%) was associated with significantly lower rates of RA-related outpatient services, office visits, diagnostic imaging studies, and joint reconstructions compared with noncompliance.ConclusionOverall healthcare utilization decreased after etanercept initiation. Patients who were most compliant with etanercept had significantly lower utilization than less compliant patients.FundingAmgen, Inc
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N6544d418ba5a42bb8a102a8e584c2346
25 Nf79a764055e94a58ad9a3e41a56dee8c
26 sg:journal.1096634
27 schema:keywords MarketScan
28 McNemar test
29 MethodsThis retrospective cohort study
30 ResultsData
31 adult patients
32 age
33 analysis
34 arthritis
35 arthroplasty
36 basis
37 basis of proportion
38 changes
39 claims
40 claims analysis
41 cohort study
42 compliance
43 compliant patients
44 continuous variables
45 data
46 database
47 days
48 department visits
49 diagnostic imaging studies
50 emergency department visits
51 etanercept
52 etanercept initiation
53 healthcare utilization
54 hospital services
55 imaging studies
56 initiation
57 inpatients
58 joint arthroplasty
59 joint reconstruction
60 laboratory visits
61 low utilization
62 lower rates
63 mean age
64 noncompliance
65 office visits
66 outcomes
67 outpatient claims
68 outpatient hospital services
69 outpatient services
70 patients
71 period
72 pharmacotherapy use
73 post-index period
74 primary outcome
75 procedure
76 proportion
77 rate
78 rate of RA
79 reconstruction
80 retrospective claims analysis
81 retrospective cohort study
82 rheumatoid arthritis
83 services
84 severe rheumatoid arthritis
85 significance
86 soft tissue procedures
87 statistical significance
88 study
89 t-test
90 test
91 tissue procedures
92 total joint arthroplasty
93 treatment
94 tumor necrosis factor inhibitor etanercept
95 use
96 utilization
97 variables
98 visits
99 years
100 schema:name Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
101 schema:pagination 2093-2103
102 schema:productId N45f01f1902f84d2596d47f3a2ba7c6e7
103 N89f7f32c7c9e447f8aecd02335b416f8
104 Ncf0edffd3955427ba840506b0d9d6bc6
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090949218
106 https://doi.org/10.1007/s12325-017-0596-6
107 schema:sdDatePublished 2022-12-01T06:36
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher Ncf51f379656c4ce8979f979a40648ac4
110 schema:url https://doi.org/10.1007/s12325-017-0596-6
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N2226f3d439534a38b3475553fec34c4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Anti-Inflammatory Agents, Non-Steroidal
116 rdf:type schema:DefinedTerm
117 N26ac8bc150484144b8f78e0bb4f044ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged
119 rdf:type schema:DefinedTerm
120 N33d5478613764c2386534d5ecae4d91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Arthritis, Rheumatoid
122 rdf:type schema:DefinedTerm
123 N34879c6a7a9a4f0e8968a6ded2241768 rdf:first sg:person.013221263257.50
124 rdf:rest Nd57967404ed548248f87ffb1951fb850
125 N364890dd9e334962b641758cdc926b18 rdf:first sg:person.0725420006.82
126 rdf:rest Nb373f2fccff14d7e8efd2655e2d14ba2
127 N45f01f1902f84d2596d47f3a2ba7c6e7 schema:name doi
128 schema:value 10.1007/s12325-017-0596-6
129 rdf:type schema:PropertyValue
130 N4f957c48cd4243b099c876cd7e5bd0af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Female
132 rdf:type schema:DefinedTerm
133 N56dafb4c91b74c89bea8d36c3f73feba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Male
135 rdf:type schema:DefinedTerm
136 N64df56efa3ed4caeab6fb95e4bee4bcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antirheumatic Agents
138 rdf:type schema:DefinedTerm
139 N6544d418ba5a42bb8a102a8e584c2346 schema:volumeNumber 34
140 rdf:type schema:PublicationVolume
141 N6ee9700255e046a18719b6d978875ed9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Treatment Outcome
143 rdf:type schema:DefinedTerm
144 N738233abf1764224a5efd5a97a6e3bd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Etanercept
146 rdf:type schema:DefinedTerm
147 N7a30c135e0db45f7b873bf8c05c6593a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Retrospective Studies
149 rdf:type schema:DefinedTerm
150 N7a944a74d1dc4000a67759766ffed146 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Delivery of Health Care
152 rdf:type schema:DefinedTerm
153 N89f7f32c7c9e447f8aecd02335b416f8 schema:name dimensions_id
154 schema:value pub.1090949218
155 rdf:type schema:PropertyValue
156 Nb373f2fccff14d7e8efd2655e2d14ba2 rdf:first sg:person.0621653226.16
157 rdf:rest N34879c6a7a9a4f0e8968a6ded2241768
158 Nb8c9b68026364895a03b24f0cb61a9b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Adult
160 rdf:type schema:DefinedTerm
161 Nc088a499aa2d440fa4383f45ec0a601a rdf:first sg:person.01174636717.21
162 rdf:rest rdf:nil
163 Ncf0edffd3955427ba840506b0d9d6bc6 schema:name pubmed_id
164 schema:value 28770517
165 rdf:type schema:PropertyValue
166 Ncf51f379656c4ce8979f979a40648ac4 schema:name Springer Nature - SN SciGraph project
167 rdf:type schema:Organization
168 Nd57967404ed548248f87ffb1951fb850 rdf:first sg:person.012257341513.89
169 rdf:rest Nc088a499aa2d440fa4383f45ec0a601a
170 Nea70ee3331c446c3baa1e8b308de72f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 Nf0707316c19c4e339a2dbbc020bb0c4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Middle Aged
175 rdf:type schema:DefinedTerm
176 Nf79a764055e94a58ad9a3e41a56dee8c schema:issueNumber 9
177 rdf:type schema:PublicationIssue
178 Nfafdf169a2624e4a9b68158dbe64543d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Insurance Claim Review
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:journal.1096634 schema:issn 0741-238X
188 1865-8652
189 schema:name Advances in Therapy
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01174636717.21 schema:affiliation grid-institutes:grid.430055.7
193 schema:familyName Broder
194 schema:givenName Michael S.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174636717.21
196 rdf:type schema:Person
197 sg:person.012257341513.89 schema:affiliation grid-institutes:grid.430055.7
198 schema:familyName Papoyan
199 schema:givenName Elya
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012257341513.89
201 rdf:type schema:Person
202 sg:person.013221263257.50 schema:affiliation grid-institutes:grid.430055.7
203 schema:familyName Chang
204 schema:givenName Eunice
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013221263257.50
206 rdf:type schema:Person
207 sg:person.0621653226.16 schema:affiliation grid-institutes:None
208 schema:familyName Schenfeld
209 schema:givenName Jennifer
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621653226.16
211 rdf:type schema:Person
212 sg:person.0725420006.82 schema:affiliation grid-institutes:grid.417886.4
213 schema:familyName Accortt
214 schema:givenName Neil A.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725420006.82
216 rdf:type schema:Person
217 sg:pub.10.1007/s10067-016-3277-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1036632859
218 https://doi.org/10.1007/s10067-016-3277-y
219 rdf:type schema:CreativeWork
220 grid-institutes:None schema:alternateName DOCS Global, Inc., Pennbrook Pkwy, North Wales, PA, USA
221 schema:name DOCS Global, Inc., Pennbrook Pkwy, North Wales, PA, USA
222 rdf:type schema:Organization
223 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA
224 schema:name Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA
225 rdf:type schema:Organization
226 grid-institutes:grid.430055.7 schema:alternateName Partnership for Health Analytic Research, Beverly Hills, CA, USA
227 schema:name Partnership for Health Analytic Research, Beverly Hills, CA, USA
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...